Clinical Trial Results: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, and immunogenicity of the rSm-p80 + GLA-SE (SchistoShield) vaccine in healthy adults in Burkina Faso and Madagasc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schistosomiasis

Drugs mentioned

• rSm-p80 + GLA-SE (SchistoShield) (rSm-p80 + GLA-SE)

Snippet

Sponsor: International Vaccine Institute | Conditions: Schistosomiasis | Phase 1 | Status: COMPLETED | Results posted: 2026-04-29